ArticleWorld journal of urology2023

Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).

Giorgio Calleris et al.PubMed ↗Publisher ↗

No numbers read from the abstract.